Multiple Sclerosis (CNP-102)

Multiple Sclerosis (MS) is a debilitating autoimmune disease affecting an estimated one million people in the U.S. MS is characterized by the dysregulated immune response towards myelin proteins of the central nervous system, which causes the destruction of neurons, disrupts the flow of information within the central nervous system, and ultimately results in disease symptoms such as loss of movement, impaired vision, and fatigue. Existing therapies for MS rely on aggressive and escalating immune-suppressant regimens that cause severe side effects and compromise quality of life.

COUR’s CNP-102 is a first-in-class therapeutic approach for MS, designed to reprogram the immune system to rebuild tolerance to myelin proteins, and provide long-term therapeutic benefit by preventing immune-mediated destruction of neurons and allowing the regeneration of damaged neurons (remyelination).